PHP77 NEW DRUGS EVALUATION IN SPAIN: THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE  by Collar, JM
Paris Abstracts A251
pacemakers, implantable cardioverter-deﬁbrillators and mechanical ventilators are 
intended to be life-saving devices and proper functionality is of paramount impor-
tance. However, concern exists regarding the potential electromagnetic interaction 
between wireless technology and these devices. Our aim is to estimate the nature and 
relevance of electromagnetic interferences. METHODS: Systematic review of literature 
up to April 2009. Data sources: ISI Web of Science, Medline and Sumsearch. Study 
selection: published studies that included testing of wireless technology for electro-
magnetic interferences on critical care medical devices.  RESULTS: Nine studies (pub-
lished from 1995 to 2008) were eligible. These studies included 7889 tests in 1240 
patients. Much of the research identiﬁed was of poor quality. As there was consider-            
able heterogeneity in the equipment studied and the testing procedures, we considered 
it inappropriate to pool the data for meta-analysis. Critical care devices are vulnerable   
to electromagnetic interferences although most clinically relevant interferences    
occurred when wireless technology was used within 30 cm-1 meter of medical equip-
ment. CONCLUSIONS: There is an urgent need for testing standardisation as well as           
for unambiguous classiﬁcation of clinically relevant electromagnetic interferences. 
Additionally, there is an urgent need for studies of good methodological quality to   
inform the development of sound evidence-based policies. This study has been sup-
ported by the Spanish National ID Program (grant number STPY 1456/07). 
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OBJECTIVES: To analyse the processes used in the adoption of new and emerging            
omic or genetic technologies in the Health Systems. METHODS: We have conducted   
literature searches and have direct contact with industries producing omic technologies 
of our networks of experts GENTECS and SORTEK for sharing information. Fur-
thermore, we have checked various guidelines and strategies deﬁned to regulate the  
introduction of such technologies in health systems established by members of 
EuroScan or other agencies. RESULTS: Many omic technologies have been “on the 
horizon” and have shown promising results at the experimental level so are of interest 
to horizon scanners. But in many cases, those promising results haven’t then developed 
into real products to be applied in the health care sector. Many factors have con-
tributed to this failure to cross the barrier, the paradigm in the system diagnosis-
pathology, the lack of treatment or management options and the promising sector of 
individualized medicine or pharmacogenetics. Different actions and initiatives estab-
lished by some HTA agencies in terms of developing guidelines and rationales that 
could help producers and systems in the adoption of these kinds of technologies have 
been studied and compared. We have found some guidelines and projects that could 
help in the adoption of omic technologies as the GEN guideline, the National Task 
Force on Genomics of the European Union, and some others, and we have identify 
some omic technologies for the diagnosis and prognosis of different genetically 
complex diseases. CONCLUSIONS: New and emerging omic technologies have      
opened new possibilities to more accurate diagnosis and treatments; moreover they  
have provided invaluable information that could guide preventative actions on 
health. However, we should consider the ethical and social consequences that could 
be caused by implementing preventative actions based on susceptibilities and not on 
certainties.
PHP76
DESIGN AND TESTING OF AN INDICATOR (FINANCIAL BIAS 
INDICATOR (FBI)) THAT ESTIMATES THE INFLUENCE OF FUNDING IN 
THE RESULTS (FINANCING BIAS (FB)) OF ECONOMIC EVALUATIONS 
OF HEALTH TECHNOLOGIES (EEHT)
Canon O1, Bueno J2, Oviedo E3, Giraldo V2
1Investigaciones para la salud y la equidad, Bogotá, Colombia, 2Investigaciones para la salud y 
la equidad, Bogota, Colombia, 3Universidad Nacional De Colombia, Bogota, Colombia
OBJECTIVES: To propose and test an indicator (FBI) to determine the frequency of 
FB in the studies of EEHTs. METHODS: Using an interdisciplinary panel we propose 
an FB indicator (FBI) on a group of EEHT. The FBI is the probability that the results 
of a randomly selected paper afford economic beneﬁts to its funder. The FBI can’t be 
used to judge individual papers, but instead allows a comparison of FB among differ-
ent sets of studies (Journals, by periods, by countries, etc). In calculating FBI the 
numerator is the sum of the studies that favor the funder and those omitting their 
source of funding; the denominator is the total papers. The test was conducted on the 
2008 European EEHTs indexed in PubMed. RESULTS: We designed the FBI to esti-
mate FB at EEHTs. We identiﬁed 88 potential EEHTs, of which 56 abstracts met the 
inclusion criteria, 52 of these were full papers thus submitted to analysis. Testing 
found: 73.07% of the papers stated the source of funding and of these, 76.31% were 
funded by health technologies companies, 96.55% of these papers reported results 
beneﬁting the funding company. The FBI for Europe in 2008 was 80.76%. FB 
decreased between the ﬁrst and second half of 2008, from 81.25% to 72.22%. CON-
CLUSIONS: We’ve presented an indicator that estimates FB probability in EEHTs. 
The FBI is applicable to sets of papers, it determines their FB and facilitates research 
control. Its systematic measurement can generate incentives to decrease FB. In order 
to facilitate FBI measurement it is convenient for authors to include within the 
abstracts: source of funding, whether the funder commercially exploits one of the 
comparators, whether any of the authors work for a company proﬁting from one of 
the comparators, and whether the results of the study favor the funder or the 
employer.
PHP77
NEW DRUGS EVALUATION IN SPAIN: THE JOINT COMMITTEE OF 
NEW DRUGS EVALUATION EXPERIENCE
Collar JM
Grunenthal Pharma, S.A., Madrid, Spain
OBJECTIVES: To evaluate the activity of the Joint Committee for New Drugs Evalu-
ation (JCNDE) in Spain. Analyze the drugs evaluated since the JCNDE was founded, 
their scores and their potential correlation with the American CDER-FDA scores. 
Analyze the timings between the new drugs commercialization and its evaluation 
publication by the JCNDE members. METHODS: The JCNDE Standard Operation 
Procedures were web-based obtained. The drugs evaluations were collected gathering 
information from different publications and from the Regional Drug evaluating 
centres involved, covering the drugs evaluated for four whole years (2004–2007). 
Commercialization date in Spain were obtained from IMS database. RESULTS: Most 
of the 60 drugs evaluated had a high prescription potential in the Primary Care (PC) 
setting and were reimbursed by the Spanish National Health System. The decision 
algorithm has 4 key criteria to evaluate the new drugs: efﬁcacy, safety, convenience 
and costs. The drugs were scored ranging from 0 (insufﬁcient experience with the 
drug) to 4 (relevant therapeutic improvement). 89% of the drugs evaluated had 0–1 
scores, and none of the drugs evaluated reached the maximum score. The median time 
of drug evaluation publication was 7 months since product launch (ranging from 7 
to 51 months). Andalusia and the Basque Country have been the most active and 
fastest Regions to publish the JCNDE evaluations. CONCLUSIONS: The JCNDE is 
a valuable instrument to increase efﬁciency in new drugs evaluations in the PC setting. 
Most of the evaluations are negative and these evaluations may be the payer argument 
to establish drug cost containment strategies, based on the low differential efﬁcacy of 
the new drugs. Although drug costs are one of the criteria to evaluate the drugs, in 
fact, health economics arguments are not relevant for the JCNDE.
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OBJECTIVES: The objective of this study was to assess to what extent HTA outcomes 
have been incorporated in drug reimbursement decision-making process in Poland. 
METHODS: To assess HTA impact, following research questions were investigated: 
1) How many different health problems currently prioritized by policy-makers have 
received HTA Agency’s attention? and 2) How many different drug technologies with 
HTA recommendations have been included on the current reimbursement lists? In total, 
83 HTA recommendations disseminated by the Appraisal Body of HTA Agency in 
Poland concerning drug technologies in the period from September 6, 2007 until Febru-
ary 2, 2009 were studied. The most recent reimbursement lists issued 23 February 2009 
by Ministry of Health and 7 July 2008 by National Health Fund were utilized. The list 
of prioritised health problems issued 23 February 2009 by Ministry of Health was 
studied as well. HTA recommendations were divided into positive and negative guid-
ance. Drug technologies, appraised by HTA Agency, were classiﬁed into two groups: 
1) eligible (a drug technology indicated for a prioritized health problem), and 2) not 
eligible (a drug technology not indicated for a prioritized health problem). RESULTS: 
As many as 59% and 54% of different indications were prioritized by Ministry 
of Health without any input from HTA process. In total, 40 negative and 43 positive 
HTA recommendations were issued. Only 18 of 43 (42%) drug technologies with a 
positive guidance were included on the reimbursement lists. At the same time as many 
as 6 of 40 (15%) of medicines with negative HTA recommendation were listed. In total, 
HTA Agency appraised 58 eligible and 25 non-eligible drug technologies. There were 
32 positive HTA recommendations in the ﬁrst group, of which 18 (56%) were included 
on the reimbursement lists. CONCLUSIONS: The HTA impact on drug reimbursement 
decisions in Poland is partially achieved and could be further enhanced.
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OBJECTIVES: To review the use of Patient Reported Outcomes (PROs) in HTA sub-
missions to date, with respect to the types of ﬁndings based on PROs, and the quality 
of the evaluations of the PRO-based evidence. METHODS: A review of the NICE 
website with respect to HTA appraisals that incorporated a PRO as part of the evi-
dence base. Focus was on appraisals that departed from the 2007 reference case, and 
the use of the EQ-5D. RESULTS: At the time of review, 142 appraisals had been 
published, with 59 in progress. In particular, two case studies were identiﬁed, somat-
ropin in growth hormone deﬁciency and Alzheimer’s disease. In GH deﬁciency, QOL 
was the primary outcome of interest and 23 scales were evaluated across 17 RCTs. 
In spite of pooling and use of generic instruments, there was insufﬁcient evidence to 
conclude that somatropin had an effect on quality of life (QOL). In observational 
study, EQ-5D results were 40% higher than disease-speciﬁc QOL-AGHDA; committee 
recommended use of QOL-AGHDA, and treatment guidelines that recommended 
treatment for fewer patients than currently being treated. In Alzheimer’s, multiple 
scales used, but treatment beneﬁts on QOL less clear (with donepezil for example, 
one study showed beneﬁt, one was neutral, one showed worsening). CONCLUSIONS: 
PRO information has been incorporated in HTA appraisals, but there are signiﬁcant 
limitations on the quality of evidence using PROs, due to study design (small sample 
size primarily), and lack of evidence for mapping value based on PROs.
